[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1109454T1 - Θεραπεια για τη νοσο του αλτσχαϊμερ και της αγγειακης εγκεφαλικης αμυλοειδοπαθειας - Google Patents

Θεραπεια για τη νοσο του αλτσχαϊμερ και της αγγειακης εγκεφαλικης αμυλοειδοπαθειας

Info

Publication number
CY1109454T1
CY1109454T1 CY20091101026T CY091101026T CY1109454T1 CY 1109454 T1 CY1109454 T1 CY 1109454T1 CY 20091101026 T CY20091101026 T CY 20091101026T CY 091101026 T CY091101026 T CY 091101026T CY 1109454 T1 CY1109454 T1 CY 1109454T1
Authority
CY
Cyprus
Prior art keywords
alzheimer
disease
treatment
amyloidopathy
vascular cerebral
Prior art date
Application number
CY20091101026T
Other languages
English (en)
Inventor
Barrio Manuel Sarasa
Original Assignee
Araclón Biotech, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclón Biotech, S.L. filed Critical Araclón Biotech, S.L.
Publication of CY1109454T1 publication Critical patent/CY1109454T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση σχετίζεται με τη χρήση αντισωμάτων στην παρασκευή ενός φαρμάκου για τη θεραπεία της νόσου του Αλτσχάϊμερ. Πιο συγκεκριμένα, η εφεύρεση σχετίζεται με τη χρήση ενός αντισώματος το οποίο αναγνωρίζει συγκεκριμένα οποιανδήποτε από τις βασικές παραλλαγές του πεπτιδίου βήτα-αμυλοειδούς Αβ40 και Αβ42, κατά την ετοιμασία ενός φαρμάκου το οποίο χρησιμοποιείται για την πρόληψη και/ή τη θεραπεία της νόσου του Αλτσχάϊμερ.
CY20091101026T 2003-05-08 2009-10-02 Θεραπεια για τη νοσο του αλτσχαϊμερ και της αγγειακης εγκεφαλικης αμυλοειδοπαθειας CY1109454T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301054A ES2246105B1 (es) 2003-05-08 2003-05-08 Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
EP04730882A EP1623719B1 (en) 2003-05-08 2004-05-03 Treatment of alzheimer's disease and cerebral amyloid angiopathy

Publications (1)

Publication Number Publication Date
CY1109454T1 true CY1109454T1 (el) 2014-08-13

Family

ID=32982086

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101026T CY1109454T1 (el) 2003-05-08 2009-10-02 Θεραπεια για τη νοσο του αλτσχαϊμερ και της αγγειακης εγκεφαλικης αμυλοειδοπαθειας

Country Status (19)

Country Link
US (6) US20090162362A1 (el)
EP (5) EP2075007B9 (el)
JP (5) JP2006525288A (el)
CN (2) CN101264326A (el)
AT (1) ATE435024T1 (el)
AU (2) AU2004237373A1 (el)
BR (1) BRPI0410684A (el)
CA (1) CA2524571C (el)
CY (1) CY1109454T1 (el)
DE (1) DE602004021797D1 (el)
DK (3) DK2075007T3 (el)
ES (6) ES2246105B1 (el)
IL (8) IL171651A (el)
MX (1) MXPA05010914A (el)
PL (3) PL2075007T3 (el)
PT (3) PT2356996E (el)
RU (2) RU2385161C2 (el)
SI (1) SI1623719T1 (el)
WO (1) WO2004098631A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246105B1 (es) * 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
EP1781704A2 (en) 2004-07-30 2007-05-09 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
PL2361638T3 (pl) * 2005-12-12 2014-08-29 Ac Immune Sa Przeciwciała monoklonalne swoiste wobec A beta 1-42 o właściwościach terapeutycznych
MX2009000476A (es) * 2006-07-14 2009-01-28 Ac Immune Sa Anticuerpo humanizado contra beta amiloide.
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
MX2009009234A (es) 2007-03-01 2009-12-01 Probiodrug Ag Uso nuevo de inhibidores de ciclasa de glutaminilo.
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RU2604181C2 (ru) * 2007-10-05 2016-12-10 Дженентек, Инк. Применение антитела против амилоида бета при глазных заболеваниях
RU2571859C2 (ru) * 2007-10-05 2015-12-20 Дженентек, Инк. Применение антитела против амилоида-бета при глазных заболеваниях
EP2149380A1 (en) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
PT2510359E (pt) 2009-12-11 2015-12-02 Araclón Biotech S L Métodos e reagentes para a deteção melhorada de péptidos beta-amiloides
EP2542549B1 (en) 2010-03-03 2016-05-11 Probiodrug AG Inhibitors of glutaminyl cyclase
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012009442A2 (en) * 2010-07-14 2012-01-19 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
PL237739B1 (pl) 2018-06-06 2021-05-17 Univ Gdanski Genisteina do zastosowania do leczenia choroby Alzheimera

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339014C (en) * 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
AU5525090A (en) * 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
US7427392B1 (en) * 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6274119B1 (en) * 1998-08-20 2001-08-14 The Regents Of The Univ. Of California Methods for labeling β-amyloid plaques and neurofibrillary tangles
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
CA2500462A1 (en) * 2001-12-26 2004-03-25 Universidad De Zaragoza Polyclonal antibodies, preparation method thereof and use of same
EP1371986A1 (en) * 2002-06-06 2003-12-17 ABETA GmbH Diagnosis of Alzheimer's disease based on the hAbeta42:hAbeta40 ratio
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ES2201929B1 (es) * 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
AU2003279216A1 (en) * 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
KR20050118669A (ko) * 2003-02-01 2005-12-19 뉴랄랩 리미티드 가용성 ａ-베타에 대한 항체를 생성하기 위한 능동 면역화
ES2246105B1 (es) * 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.

Also Published As

Publication number Publication date
IL207877A0 (en) 2011-07-31
IL207876A0 (en) 2011-07-31
EP2075007A3 (en) 2009-11-11
DK2075007T3 (da) 2013-07-29
EP2075007B1 (en) 2013-05-22
DK2356996T3 (da) 2013-07-22
US20140044725A1 (en) 2014-02-13
US20110262458A1 (en) 2011-10-27
ES2246177A1 (es) 2006-02-01
IL207881A (en) 2013-02-28
RU2526155C2 (ru) 2014-08-20
IL171651A (en) 2011-11-30
AU2011200170C1 (en) 2012-03-22
IL207880A0 (en) 2011-07-31
US20090162362A1 (en) 2009-06-25
IL207879A0 (en) 2011-07-31
MXPA05010914A (es) 2006-03-21
EP2305286A2 (en) 2011-04-06
IL207881A0 (en) 2011-07-31
EP1623719A1 (en) 2006-02-08
RU2005134351A (ru) 2006-04-27
IL207878A (en) 2013-02-28
IL207875A (en) 2013-02-28
ES2246178A1 (es) 2006-02-01
JP2018119011A (ja) 2018-08-02
US20170260234A1 (en) 2017-09-14
ES2246105A1 (es) 2006-02-01
CA2524571C (en) 2017-01-10
EP2082747A2 (en) 2009-07-29
ES2246177B1 (es) 2007-03-01
PT2356996E (pt) 2013-08-23
AU2004237373A1 (en) 2004-11-18
IL207875A0 (en) 2011-07-31
JP2016065100A (ja) 2016-04-28
EP2075007A2 (en) 2009-07-01
EP1623719B1 (en) 2009-07-01
DK2356996T5 (da) 2013-08-26
EP2075007B9 (en) 2013-09-04
IL207879A (en) 2013-02-28
EP2356996A1 (en) 2011-08-17
ES2329369T3 (es) 2009-11-25
ES2423281T3 (es) 2013-09-19
JP2012006967A (ja) 2012-01-12
EP2356996B9 (en) 2013-08-28
AU2011200170B2 (en) 2011-09-01
EP2082747A3 (en) 2010-01-13
BRPI0410684A (pt) 2006-06-20
CN1784240A (zh) 2006-06-07
JP2014129389A (ja) 2014-07-10
IL207878A0 (en) 2011-07-31
ATE435024T1 (de) 2009-07-15
ES2246105B1 (es) 2007-03-01
RU2009148539A (ru) 2011-06-27
DK1623719T3 (da) 2009-11-09
PT2075007E (pt) 2013-08-23
CA2524571A1 (en) 2004-11-18
RU2385161C2 (ru) 2010-03-27
JP2006525288A (ja) 2006-11-09
AU2011200170A1 (en) 2011-02-03
WO2004098631A1 (es) 2004-11-18
PL1623719T3 (pl) 2010-11-30
IL207880A (en) 2013-02-28
SI1623719T1 (sl) 2009-12-31
EP2356996B1 (en) 2013-06-26
PT1623719E (pt) 2009-10-08
IL207876A (en) 2013-03-24
ES2423590T3 (es) 2013-09-23
DE602004021797D1 (de) 2009-08-13
ES2246178B1 (es) 2007-03-01
US20200140488A1 (en) 2020-05-07
PL2075007T3 (pl) 2013-09-30
IL207877A (en) 2013-03-24
EP2305286A3 (en) 2011-11-09
PL2356996T3 (pl) 2013-09-30
US20210214394A1 (en) 2021-07-15
CN101264326A (zh) 2008-09-17

Similar Documents

Publication Publication Date Title
CY1109454T1 (el) Θεραπεια για τη νοσο του αλτσχαϊμερ και της αγγειακης εγκεφαλικης αμυλοειδοπαθειας
CY1105922T1 (el) Χρηση υποκατεστημενων παραγωγων αζετιδινονης στη θepαπεια ασθενειας alzheimer
TR200103469T2 (tr) Amiloidojenik hastalığının önlenmesi ve tedavisi
CY1116776T1 (el) Αντισωματα ειδικα για τα διαλυτα πρωτοϊνιδια των πεπτιδιων β-αμυλοειδους και χρησεις αυτων
BR0016022A (pt) Vacina para a prevenção e tratamento da doença de alzheimer e doenças relacionadas ao amilóide
CY1108740T1 (el) ΕΞΑΝΘΡΩΠΙΣΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΤΑ ΟΠΟΙΑ ΑΝΑΓΝΩΡΙΖΟΥΝ ΤΟ ΠΕΠΤΙΔΙΟ β-ΑΜΥΛΟΕΙΔΟΥΣ
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
PT721449E (pt) Inibidores da producao da proteina beta-amiloide
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
ATE369380T1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
CY1108331T1 (el) Προληψη και θεραπεια αμυλοειδογονου νοσου
CY1113143T1 (el) Μεθοδος προσδιορισμου της νοσου toy alzheimer
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
EA200501560A1 (ru) Предотвращение и терапия амилоидогенной болезни
CY1109045T1 (el) Ρετινοειδη για τη θεραπεια του εμφυσηματος
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
CY1107231T1 (el) Υποκατεστημενα παραγωγα 4-αμινοκυκλοεξανολης
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
EA200601238A1 (ru) Медикаменты для профилактики и лечения бромидроза и для улучшения запаха тела
ATA8192003A (de) Verwendung von oxicam-verbindungen
ATE443695T1 (de) Doppelester